X0306 4 2020-02-20 0 0000896262 AMEDISYS INC AMED 0001543701 Ginn Scott G 3854 AMERICAN WAY, SUITE A BATON ROUGE LA 70816 0 1 0 0 Chief Financial Officer Common Stock 2020-02-20 4 F 0 222 194.12 D 18664 D Common Stock 2020-02-21 4 M 0 11250 27.35 A 29914 D Common Stock 2020-02-21 4 S 0 3200 193.24 D 26714 D Common Stock 2020-02-21 4 S 0 5921 194.12 D 20793 D Common Stock 2020-02-21 4 S 0 2129 194.72 D 18664 D Common Stock 2714 I Through 401(k) Plan Stock Option (right to buy) 27.35 2020-02-21 4 M 0 11250 0.00 D 2019-05-01 2025-05-01 Common Stock 11250 11250 D The total amount of shares beneficially owned includes 887 shares held in an employee stock purchase plan account. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.58 to $193.57, inclusive. The reporting person undertakes to provide to Amedisys, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.59 to $194.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.59 to $195.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4. The information in this report is based on a plan statement dated as of December 31, 2019. On May 1, 2015, the reporting person was granted an option to purchase 22,500 shares of common stock, subject to time-based vesting. The option vested as to 11,250 shares on May 1, 2019, and the remaining 11,250 options will vest on May 1, 2020, provided that on such vesting date, the reporting person remains continuously employed by the Issuer. /s/ Jennifer R. Guckert, pursuant to a power of attorney 2020-02-24